4552   JCR Pharmaceuticals Co.,Ltd.

09/12/2025 11:00	JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
09/08/2025 16:00	JCR Pharmaceuticals Sponsors and Participates in Relay For Life of Ashiya
09/08/2025 16:00	JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
09/04/2025 16:00	Notice of Organizational and Personnel Changes
09/01/2025 16:00	Notice of Personnel Change
09/01/2025 14:00	PHC and JCR GROWJECTOR L Automated Injection Device Wins 2025 Kids Design Award
08/29/2025 15:30	MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
08/28/2025 11:00	JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
08/01/2025 17:00	Corporate Governance Report
07/30/2025 16:00	FY2025 First Quarter Results Conference Call Material
07/30/2025 16:00	Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2025 (FY2025) (Japanese standard)
07/28/2025 16:00	JCR Receives National Honor for Supporting Children with Complex Medical Needs
07/25/2025 16:00	Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
07/08/2025 16:00	JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
07/02/2025 16:00	JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
06/25/2025 16:00	Matters Concerning Controlling Shareholders (Affiliated Companies)
06/25/2025 16:00	Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation
06/25/2025 16:00	Notice of Personnel Change
06/24/2025 15:30	Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)
06/18/2025 12:00	JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
06/06/2025 16:50	[Updated]JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
06/06/2025 12:00	JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
06/04/2025 08:00	Other Matters Subject to Measures for Electronic Provision When Convening the 50th Ordinary General Meeting of Shareholders
06/04/2025 08:00	Notice of Convocation of The 50th Ordinary General Meeting of Shareholders
05/16/2025 13:00	[Updated]FY2024 Results Briefing Session Material
05/15/2025 12:00	JCR Pharmaceuticals Presents Preclinical Gene Therapy Data at ASGCT 28th Annual Meeting
05/14/2025 09:00	[Delayed]Notice of Recognition of Gain on Deferred Income Taxes
05/13/2025 16:00	JCR Pharmaceuticals Announces Chairman and President Transition as of April 1, 2026
05/13/2025 16:00	FY2024 Results Briefing Session Material
05/13/2025 16:00	Financial Summary Consolidated Financial Results for the Year ended March 31, 2025 (FY2024) (Japanese standard)
05/13/2025 16:00	JCR Pharmaceuticals Announces New Corporate Philosophy and Core Values
05/13/2025 16:00	Notice of Distribution of Retained Earnings
05/08/2025 12:00	JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
05/07/2025 15:30	Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
04/25/2025 16:00	Notice of Election of Candidate for New Audit & Supervisory Board Members
03/27/2025 16:00	JCR Revises Full-Year Consolidated Forecast for FY2024
02/27/2025 16:00	Change in Duties of Corporate Officers, Organizational and Personnel Changes
02/25/2025 16:00	Notice Concerning the Start of Construction of a New Drug Product Plant
02/21/2025 13:00	JCR Pharmaceuticals Proudly Supports Rare Disease Day 2025
01/31/2025 16:00	Summary of Financial Results for the third quarter 2025
01/31/2025 16:00	Financial Summary Consolidated Financial Results for the Nine Months ended December 31, 2024 (FY2024) (Japanese standard)
01/31/2025 16:00	Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2025
01/31/2025 16:00	FY2024 Third Quarter Consolidated Financial Results Conference Call
01/28/2025 21:30	JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposiumTM 2025
01/06/2025 13:00	[Updated]JCR and Modalis Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
01/06/2025 12:00	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
12/25/2024 14:00	JCR Pharmaceuticals Receives MHLW Orphan Drug Designation for JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
12/19/2024 16:00	JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy
12/03/2024 16:00	MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for MPS IIIB in Japan
11/21/2024 16:00	FY2024 R&Dmeeting Meterial
11/19/2024 13:00	JCR Sponsors Family Health Activities at ORGAN ROOMS PROJECT
11/18/2024 14:30	[Delayed]Financial Summary Consolidated Financial Results for the Six Months ended September 30, 2024 (FY2024) (Japanese standard)
11/01/2024 09:30	Notice Regarding the Result and Completion of Repurchase of Own Shares through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/31/2024 16:00	Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/31/2024 15:30	JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA
10/30/2024 16:30	Financial Summary Consolidated Financial Results for the Six Months ended September 30-2024_FY2024_Japanese standard_Flash Report
10/30/2024 16:30	FY2024 Second Quarter Results Briefing Session
10/30/2024 16:00	Summary of Financial Results for the second quarter 2025
10/30/2024 16:00	Notice of Repurchase of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
10/30/2024 16:00	Notice of Personnel Change
10/30/2024 16:00	Notice of Distribution of Retained Earnings (Interim Dividend)
10/23/2024 11:30	JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress
10/16/2024 16:00	JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress